Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
The Cambridge Enterprise film, #nextgreatidea, was awarded gold at the EVCOM Screen Awards 2016, held at Lindley Hall in Westminster.
10 May 2016Read in full
Apollo Therapeutics, the investment fund focused on driving therapeutic innovation through university collaboration, has appointed Dr Richard Butt as CEO, effective from 23 May 2016.
15 April 2016Read in full
The Cambridge Enterprise film, #nextgreatidea, launched in November 2015 to showcase some of the world-changing ideas it has supported in the journey to market, has been nominated in the 'Brand Communication' category at the EVCOM Screen Awards 2016.
8 April 2016Read in full
ROADMap has announced that it has successfully closed a funding round of $1.7 million by securing investment from a number of institutional and private investors. The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, which also led the earlier funding rounds. The investment will help fund the expansion of the business as it takes its revolutionary wavelength selective switch (WSS) technology to market.
8 April 2016Read in full
Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in Cambridge, has obtained a grant from the Wellcome Trust Pathfinder Award Scheme. Quethera was founded in 2013 to treat glaucoma using gene therapy. It received seed funding last year from the Rainbow Seed Fund and Cambridge Enterprise, the commercialisation arm of the University of Cambridge.
8 March 2016Read in full
Silicon MicroGravity (SMG), a newly-formed University of Cambridge spin-out that has developed a novel sensor technology used by oil companies to enhance oil recovery, has received initial funding of $3 million from Imperial Innovations Group plc and Cambridge Enterprise, the commercialisation arm of the University of Cambridge, together with grant funding from the UK government.
1 March 2016Read in full
The University of Cambridge Enterprise Fund IV has been launched by Parkwalk Advisors, a London-based independent investment management firm, in conjunction with Cambridge Enterprise.
29 February 2016Read in full
Cambridge Touch Technologies Ltd CTT), a University of Cambridge start-up poised to make 3D touch technology a standard feature on smart devices, has received seed investment by Cambridge Enterprise, the commercialisation arm of the University.
3 February 2016Read in full
For the third consecutive year, the University of Cambridge has broken its early stage investment record, approving 13 seed fund investments for a total of £3.8 million, an increase on the £3.2 million invested in 2013-14.
28 January 2016Read in full
Three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation) and the technology transfer offices of three world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces with a combined £40 million to create the Apollo Therapeutics Fund (Apollo).
25 January 2016Read in full